Discover how biologic therapy, JAK inhibitors, and modern targeted treatments are transforming rheumatology. INTRODUCTION In clinical practice, the management of systemic autoimmune diseases has undergone a fundamental shift over the past three decades. Historically, rheumatology was a specialty focused on symptom management and rehabilitation. We relied heavily on gold salts, high-dose glucocorticoids, and non-steroidal anti-inflammatory drugs (NSAIDs) to mitigate pain, whil

Beyond the Joints It is a common misconception that diseases like Rheumatoid Arthritis and Psoriatic Arthritis are confined entirely to the musculoskeletal system. Accumulating epidemiological data indicates that systemic inflammation inherently drives accelerated atherogenesis, placing rheumatology patients at a significantly higher risk for cardiovascular disease (CVD) than the general public. The Pathophysiological Connection Chronic elevation of pro-inflammatory cytokines

Diagnosing Rheumatoid Arthritis (RA) typically relies heavily on serum biomarkers, specifically Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies. However, approximately 20% to 30% of RA patients present with seronegative RA, meaning they display classic clinical symptoms of inflammatory arthritis but test negative for these traditional autoantibodies. In clinical practice, seronegative RA poses a significant diagnostic challenge, often leadin

Why Early Treatment Changes Everything ? Rheumatoid Arthritis (RA) is not just joint pain, it is a systemic autoimmune disease that can cause irreversible joint damage if not treated early. Affects ~0.5% to 1% of the global population Women are affected 2–3 times more than men Peak onset: 30–50 years of age Up to 60% joint damage occurs in the first 2 years if untreated What is the “Window of Opportunity”? Modern rheumatology shows that the first 12 weeks after symptom onset